CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Frequently asked questions
What sector does Cns Pharmaceuticals Inc (CNSP) operate in?
Cns Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cns Pharmaceuticals Inc (CNSP) current stock price?
As of the latest data, Cns Pharmaceuticals Inc stock price is $5.70, with a previous close of $5.86. Cns Pharmaceuticals Inc lost -$0.16 in the last trading session, representing a -2.75% loss.
What is Cns Pharmaceuticals Inc (CNSP) current market capitalization?
Cns Pharmaceuticals Inc market cap is approximately 8.33 million.
What is Cns Pharmaceuticals Inc (CNSP) Earnings Per Share (EPS)?
The trailing EPS is -$24.12, and the forward EPS is -$1.66.
What is Cns Pharmaceuticals Inc (CNSP) EBITDA?
Cns Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.55 million.
Does Cns Pharmaceuticals Inc (CNSP) pay dividends?
No. Cns Pharmaceuticals Inc does not pay a dividend.
What is Cns Pharmaceuticals Inc (CNSP) beta (volatility) score?
Cns Pharmaceuticals Inc has a beta of 0.980, meaning its volatility is roughly in line with the market.
